“We are grateful to the OCS for its continued support of BrainStorm. The non-dilutive capital that our company has received from the OCS helps advance our NurOwn™ technology as a new treatment paradigm for patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders,” said Chaim Lebovits, President of BrainStorm.
BrainStorm is performing a Phase I/II human clinical trial in Israel with the Company's adult stem cell therapy in patients with ALS, often referred to as Lou Gehrig's Disease. The study is conducted in cooperation with the world-renowned Hadassah Medical Center and headed by the principal investigator Dimitrios Karussis, M.D., Ph.D., of the Hadassah Medical Center, and a scientific team from BrainStorm headed by Prof. Eldad Melamed. The initial phase of the study is designed to establish the safety of NurOwn™ and will later be expanded to assess efficacy.
Ref and Read more: http://pharmalive.com/News/Index.cfm?articleid=804823